SGIO.Y Stock Overview Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. More details
Rewards Risk Analysis No risks detected for SGIO.Y from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Shionogi & Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Shionogi Historical stock prices Current Share Price JP¥6.93 52 Week High JP¥9.11 52 Week Low JP¥6.22 Beta 0.28 1 Month Change -3.35% 3 Month Change -0.14% 1 Year Change -17.43% 3 Year Change -37.11% 5 Year Change -35.15% Change since IPO -8.87%
Recent News & Updates Shionogi & Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025 Shionogi & Co., Ltd. Announces Dividend for the Second Quarter of Year Ending March 31,2025, Payable on December 2,2024; Provides Dividend Guidance for the Full Year Ending March 31,2025
Shionogi & Co., Ltd. Announces Presents Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously III Patients Oct 17
Shionogi & Co., Ltd. Submits New Drug Application in Japan for Zuranolone as A Treatment for Major Depressive Disorder Sep 27 Shionogi & Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2025
Shionogi & Co., Ltd. to Report Q2, 2025 Results on Oct 28, 2024 Aug 28 See more updates Shionogi & Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025 Shionogi & Co., Ltd. Announces Dividend for the Second Quarter of Year Ending March 31,2025, Payable on December 2,2024; Provides Dividend Guidance for the Full Year Ending March 31,2025
Shionogi & Co., Ltd. Announces Presents Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously III Patients Oct 17
Shionogi & Co., Ltd. Submits New Drug Application in Japan for Zuranolone as A Treatment for Major Depressive Disorder Sep 27 Shionogi & Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2025
Shionogi & Co., Ltd. to Report Q2, 2025 Results on Oct 28, 2024 Aug 28
Shionogi & Co., Ltd. to Report Q1, 2025 Results on Jul 29, 2024 Jun 13
Shionogi & Co., Ltd., Annual General Meeting, Jun 20, 2024 May 15
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 Apr 26
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study (PERSEUS) of Fetroja®/F etcroja® (cefiderocol) Apr 21
Shionogi & Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024 Mar 24
Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan Feb 29
Shionogi & Co., Ltd. Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open Feb 10
Shionogi & Co., Ltd Announces the Launch of Fetroja(Cefiderocol) Intravenous Infusion 1g Vial in Japan on December 20, 2023 Dec 20
Shionogi & Co., Ltd. Initiation of a Phase 3 Additional Dose Clinical Trial in Japanese Subjects of the Monovalent Vaccine for the XBB1.5 Strain, S-268023 Dec 18
Shionogi & Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024 Nov 29
Shionogi & Co., Ltd. Presents New Real-World Evidence Demonstrating Effectiveness of Early Treatment with Fetroja®? (Cefiderocol) in Appropriate Patients Oct 12
Shionogi & Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023 Sep 08
Shionogi & Co., Ltd. (TSE:4507) announces an Equity Buyback for 12,500,000 shares, representing 4.2% for ¥7,500 million. Aug 01
Eddingpharm Announces Approval of Mulpleta®? (Lusutrombopag) in China Jun 30
Shionogi & Co., Ltd. Announces Initiation of a Phase 3 Clinical Trial in Japanese Pediatric Patients of Ensitrelvir for COVID-19 Jun 29
Shionogi & Co., Ltd. Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection Jun 10
Shionogi & Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023 Jun 09 Shionogi & Co., Ltd. Announces Year-End Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023; Provides Dividend Guidance for the End of Second Quarter of Fiscal Year 2024
Shionogi & Co., Ltd., Annual General Meeting, Jun 21, 2023 May 10
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program Feb 16 Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
Shionogi & Co., Ltd. Announces Availability of Innovative Antibiotic, Cefiderocol in Norway Jan 18
Shionogi & Co., Ltd. Announces Initiation of Phase1/2/3 Clinical Trial (Part 2), Phase 3 Additional Dose Clinical Trial in Japanese Pediatric of the COVID-19 Vaccine, S-268019 Jan 17
Shionogi & Co., Ltd. to Report Q3, 2023 Results on Jan 30, 2023 Dec 08
Shionogi & Co., Ltd. Files for Approval of S-268019, A COVID-19 Recombinant Protein-Based Vaccine, in Japan Nov 24
Shionogi & Co., Ltd. Announces Tablets 125Mg Approved in Japan for the Treatment of SARS-CoV-2 Infection Nov 23 Shionogi & Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2022, Payable on December 1, 2022 Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for First Half of the Fiscal Year Ending March 31, 2023
Shionogi & Co., Ltd. Announces Achievement of the Primary Endpoint for Ensitrelvir (S-217622) in the Phase 3 part of the Phase 2/3 Clinical Trial in Asia Sep 28
Shionogi & Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022 Sep 14
Shionogi & Co., Ltd Announces Ensitrelvir Fumaric Acid (S-217622), Therapeutic Drug for COVID-19,Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.2.75 Aug 11 Shionogi & Co., Ltd. Provides Year-End Dividend Guidance for the Year Ending March 31, 2023
Shionogi & Co., Ltd. Initiates Fourth Vaccination Trail Jul 27
Shionogi & Co., Ltd. Announces Initiation of A Clinical Trial in Japanese Pediatric Subjects of the COVID-19 Recombinant Protein-Based Vaccine, S-268019 Jul 19
Shionogi & Co., Ltd. Announces S-217622, A Therapeutic Drug for Covid-19, Shows High in Vitro Antiviral Activity Against Omicron Subvariants BA.4 and BA.5 Jul 14
Shionogi & Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022 Jun 04
Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment May 26
Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment May 25
Shionogi & Co. Announces Initiation of a Phase 2/3 Clinical Trial in Japanese Adolescents for the Covid-19 Recombinant Protein-Based Vaccine, S-268019 May 16 Shionogi & Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2022 and Full Year Ending March 31, 2023 Shionogi & Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2022
Shionogi & Co., Ltd. Announces New Results for Oral Antiviral S-217622 Apr 24
Shionogi & Co., Ltd. Presents Japanese Phase 2/3 Clinical Trial Results of COVID-19 Recombinant Protein-Based Vaccine At Conference Apr 22
Shionogi & Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022 Apr 04
Shionogi & Co., Ltd. Report Phase 2/3 Additional Dose Clinical Trial for Covid-19 Vaccine, S-268019 Mar 06
Shionogi & Co., Ltd. Files for Approval of S-217622, a Therapeutic Drug for COVID-19, in Japan Feb 26
Shionogi & Co., Ltd. Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622 Feb 08
Shionogi & Co., Ltd. Presents Clinical Trial Results of the Covid-19 Therapeutic Drug S-217622 Feb 01 Shionogi & Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2022
Shionogi & Co., Ltd. Announces Notice Regarding the Progress of S-217622 to Fight COVID-19 Jan 22
Shionogi & Co., Ltd. Announces Notice Regarding the Initiation of Active Control Neutralizing Antibody Comparative Clinical Trial for COVID-19 Recombinant Protein-Based Vaccine Jan 18
Shionogi & Co., Ltd. Announces Initiation of a Global Phase 3 Clinical Trial for COVID-19 Recombinant Protein-Based Vaccine, S-268019 Dec 28
Shionogi & Co., Ltd. Announces Positive Results from A Phase 2 Trial of the Regeneration Inducing Medicine S-005151 (Redasemtide) with Acute Ischemic Stroke Dec 14
Shionogi & Co., Ltd. Announces Launch of Mutational Analysis Services for Wastewater-Based Epidemiological Surveillance of the Novel Coronavirus Dec 08
Shionogi & Co., Ltd. Announces Initiation of A Phase 2/3 Clinical Trial for A COVID-19 Therapeutic Agent in Japan Sep 29
Shionogi & Co., Ltd. Provides Earnings Guidance for the Six Months and Full Year of Fiscal Year Ending March 31, 2022 May 11 Shionogi & Co., Ltd. Files the Application for Marketing Approval of Th2 Chemokine TARC Kit "HISCL(R) TARC reagent"to Assist in Predicting the Exacerbation of COVID-19
Shionogi & Co., Ltd. and BioAge Labs, Inc. Conclude a License Agreement Aimed At Treating COVID-19 Jan 28
Shionogi & Co., Ltd.Shionogi B.V. Announces That Nice and Nhse&I Have Selected Its Innovative Antibiotic, Cefiderocol, for Inclusion in A Pilot Subscription Reimbursement Model Dec 23
Shionogi & Co., Ltd. Announces Initiation of Phase 1/2 Clinical Trial for COVID-19 Recombinant Protein-Based Vaccine Dec 17 Shionogi & Co., Ltd. and Nagasaki University Enter into Strategic Research Collaboration for Antimalarial Drugs with the Kitasato Institute
Shionogi & Co., Ltd. and the Roche Group Enter License and Collaboration Agreement Nov 25
Shionogi & Co., Ltd. Announces Publication of Two Studies in the Lancet Infectious Diseases Highlighting the Efficacy and Safety of Cefiderocol for the Treatment of Infections Due to Aerobic Gram-negative Bacteria in Adults With Limited Treatment Options Oct 13
Shionogi & Co., Ltd. to Report Q2, 2021 Results on Oct 30, 2020 Oct 10
Shionogi & Co., Ltd. Announces U.S. Food and Drug Administration Approval of FETROJA® for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Sep 29
Shionogi & Co., Ltd. (TSE:4507) completed the acquisition of remaining majority stake in Tetra Therapeutics Inc. Aug 12 Shareholder Returns SGIO.Y US Pharmaceuticals US Market 7D -0.6% 0.2% -0.5% 1Y -17.4% 2.0% 23.2%
See full shareholder returns
Return vs Market: SGIO.Y underperformed the US Market which returned 23% over the past year.
Price Volatility Is SGIO.Y's price volatile compared to industry and market? SGIO.Y volatility SGIO.Y Average Weekly Movement 2.4% Pharmaceuticals Industry Average Movement 10.9% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.2%
Stable Share Price: SGIO.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SGIO.Y's weekly volatility (2%) has been stable over the past year.
About the Company Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
Show more Shionogi & Co., Ltd. Fundamentals Summary How do Shionogi's earnings and revenue compare to its market cap? SGIO.Y fundamental statistics Market cap US$11.89b Earnings (TTM ) US$977.52m Revenue (TTM ) US$2.65b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SGIO.Y income statement (TTM ) Revenue JP¥418.51b Cost of Revenue JP¥59.85b Gross Profit JP¥358.66b Other Expenses JP¥204.09b Earnings JP¥154.57b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
Earnings per share (EPS) 181.70 Gross Margin 85.70% Net Profit Margin 36.93% Debt/Equity Ratio 0%
How did SGIO.Y perform over the long term?
See historical performance and comparison Dividends
2.6% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 21:34 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shionogi & Co., Ltd. is covered by 26 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Atsushi Seki Barclays Koichi Mamegano BofA Global Research Aaron Ho CFRA Equity Research
Show 23 more analysts 
